<DOC>
	<DOCNO>NCT01706120</DOCNO>
	<brief_summary>The addition bevacizumab first-line chemotherapy show improve progression free survival patient ovarian cancer . The purpose study explore potential role clinical biologic factor identify patient benefit combine therapy term progression free overall survival .</brief_summary>
	<brief_title>Study Clinical Biological Prognostic Factors Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab</brief_title>
	<detailed_description>MITO-16 - MANGO-OV2 single-arm , open-label , non-comparative , multicenter , phase IV study . Patients receive combination bevacizumab , paclitaxel carboplatin first line treatment ( in-label dose schedule ) . This exploratory study attempt identify potential prognostic clinical factor ( hypertension ) prognostic biologic factor . Overall , 2 type biomarkers consider . Dynamic biomarkers express change nature disease relation treatment simply tumour progression , typically inherit . Genetic biomarkers typically inherited expression characteristic potentially able interfere treatment effect ( i.e . Pharmacogenomics ) . The safety regimen routine clinical practice also describe .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female patient ≥18 year age . Patients histologically confirm epithelial ovarian carcinoma , fallopian tube carcinoma primary peritoneal carcinoma , include mixed Mullerian Tumours Or Recurrent early stage epithelial ovarian fallopian tube carcinoma treat surgery alone . FIGO stage IIIB &amp; C IV ECOG Performance Status 02 . Life expectancy least 12 week . Signed informed consent obtain prior initiation studyspecific procedure treatment confirmation patient 's awareness willingness comply study requirement . Availability tumour sample molecular analysis Cancer relate Ovarian tumour low malignant potential ( i.e . borderline tumour ) Previous systemic anticancer therapy advance ovarian cancer . History evidence brain metastasis spinal cord compression . History evidence synchronous primary endometrial carcinoma , unless follow criterion relate endometrial carcinoma meet : stage ≤Ia superficial myometrial invasion lymphovascular invasion poorly differentiate ( grade 3 papillary serous clear cell carcinoma ) . Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . Othertreatment relate Any prior radiotherapy pelvis abdomen . Surgery ( include open biopsy ) within 4 week prior first bevacizumab dose plan ( In case patient enrol administration bevacizumab omit first cycle ) . Current recent ( within 10 day prior first study drug dose ) use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose ( except central venous access patency , case international normalize ratio [ INR ] must maintain 1.5 ) . Post operative prophylaxis low molecular weight heparin sc allow . Current recent ( within 30 day first study dose ) treatment another investigational drug . Laboratory related Inadequate bone marrow function : ANC : &lt; 1.5 x 109/l , platelet count &lt; 100 x 109/l Haemoglobin &lt; 9 g/dl . Patients may transfuse maintain haemoglobin value ≥9 g/dl . Inadequate coagulation parameter : activate partial thromboplastin time ( APTT ) &gt; 1.5 xULN INR &gt; 1.5 Inadequate liver function , define : serum ( total ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) institution AST/SGOT ALT/SGPT &gt; 2.5 x ULN . Inadequate renal function , define serum creatinine &gt; 2.0 mg/dl &gt; 177 micromol/l Proteinuria &gt; 1g 24hour urine collection ( perform among patient show ≥3+ urine dipstick ) . Patient relate Pregnant lactating patient . History evidence thrombotic hemorrhagic disorder ; include cerebrovascular accident ( CVA ) / stroke transient ischemic attack ( TIA ) subarachnoid haemorrhage within ≤6 month prior first study treatment ) . Uncontrolled hypertension ( sustain systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg despite antihypertensive therapy ) clinically significant ( i.e . active ) cardiovascular disease , include : myocardial infarction unstable angina within ≤6 month prior first study treatment New York Heart Association ( NYHA ) grade II great congestive heart failure ( CHF ) serious cardiac arrhythmia require medication ( exception atrial fibrillation paroxysmal supraventricular tachycardia ) peripheral vascular disease ≥grade 3 ( i.e . symptomatic interfering activity daily live require repair revision ) . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior first study treatment . Nonhealing wound , ulcer bone fracture . Patients granulate incision heal secondary intention evidence fascial dehiscence infection eligible require three weekly wound examination . Evidence medical condition ( psychiatric illness , peptic ulcer , etc . ) , physical examination laboratory finding may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prognostic factor</keyword>
	<keyword>biologic factor</keyword>
	<keyword>clinical factor</keyword>
	<keyword>routine clinical practice</keyword>
</DOC>